{"id":"W4409103399","doi":"10.1016/s1470-2045(25)00030-0","title":"First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Medicine; Placebo; Prostate cancer; Internal medicine; Clinical trial; Double blind; Oncology; First line; Urology; Cancer; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001974517,0.002589657,0.00391954,0.0005223675,0.0003655276,0.001165975,0.001128932,0.001846682,0.007890047],"category_scores_gemma":[0.002061657,0.0006710895,0.003639381,0.0003861134,0.001223414,0.001369963,0.0005358068,0.003889195,0.0009906018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009889831,"about_ca_system_score_gemma":0.0008007486,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001573083,"about_ca_topic_score_gemma":0.003685339,"domain_scores_codex":[0.9992344,0.0004320075,0.0000396821,0.0001247035,0.00005136352,0.0001179008],"domain_scores_gemma":[0.9990127,0.0003231098,0.0002402804,0.00007670177,0.0000564257,0.0002907293],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9914881,0.001039418,0.0001831821,0.0004325981,0.001288033,0.00001562798,0.00001870156,0.000240266,0.0007382271,0.00004818063,0.0004746742,0.004032909],"study_design_scores_gemma":[0.9744508,0.0223938,0.001193152,0.00003172448,0.0009914115,0.00002378514,0.0000181174,0.0002637415,0.0001854574,0.0001190762,0.000313616,0.00001526085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9756443,0.01383741,0.0008045112,0.001321809,0.001211844,0.00140277,0.002533399,0.0002495284,0.002994549],"genre_scores_gemma":[0.985967,0.00418921,0.0008579976,0.00132153,0.0007242836,0.001182764,0.002017253,0.00004209235,0.003697917],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007890047,"threshold_uncertainty_score":0.02639484,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1278745526106936,"score_gpt":0.4242313951586915,"score_spread":0.2963568425479979,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}